H.B. Fuller Company (FUL)
NYSEMaterialsChemicals - SpecialtySnapshot 2026-09-04
$53.89+0.41%
Close 2026-09-04 · 1-day change
NYSEMaterialsChemicals - SpecialtySnapshot 2026-09-04
Warn: Primary pillar under pressure — Complete AMS acquisition and realize $55M synergies by 2031: Acquisition not closed vs target by 2026 year-end.
H.B. Fuller grows revenue by about 6% yearly, helped by acquisitions and pricing. Profit margins are expanding, with adjusted EBITDA margin improving to 15.4%. Free cash flow is strong, with a full-year target of $312.5 million. The acquisition of Advanced Medical Solutions adds $15 billion to the market and aims for $55 million in synergies.
Activist pressure may block the key acquisition, slowing growth. Profit margin expansion to over 20% remains uncertain. Cash flow could weaken if working capital management stalls or costs rise.
The stock trades about 17% below our fair value near $70, reflecting an 8% revenue growth expectation. Our view aligns with consensus on growth but sees risk in margin and acquisition delivery.
Breaks if: EBITDA margin fails to progress beyond 16% by 2028
Drive margin expansion through portfolio mix shift, cost management, and strategic acquisitions to exceed 20% EBITDA margin.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on strategic acquisitions and revenue growth. The current thesis state reflects a mixed outlook due to recent strong financial performance but fragile earnings quality.
The market currently prices FUL as cheap compared to its peers, reflecting a low expectations gap. This suggests that investors are not fully factoring in the potential for improved execution and margin expansion.
Fundamentals are likely to show continued revenue growth driven by strategic pricing and acquisitions. However, the earnings quality remains fragile, which could pose risks despite recent strong performance.
The thesis hinges on management's ability to execute on their acquisition strategy and achieve targeted EBITDA margins. Additionally, external factors such as inflation trends and performance of sector peers will play a crucial role in shaping outcomes.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat strengthens the read on FUL. However, the potential divestiture of the adhesives unit poses a threat to growth.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of last 2 quarters. Adjusted EBITDA margin improved from 14.5% in 2025-Q1 to 15.4% in 2026-Q1, reflecting margin expansion efforts. Management's focus on cost management and portfolio mix shift supports progress toward the >20% EBITDA margin target, though the goal remains aspirational.
“Accelerated path to structurally higher growth and margins with target >20% EBITDA margin.”
“We continued to expand margins by leveraging global sourcing strength and focused cost management.”
Breaks if: Operating cash flow falls below $250 million in FY26
Generate operating cash flow of $300M-$325M in 2026 and optimize net working capital to support deleveraging and capital allocation.
Stated in 2 of last 2 quarters. Operating cash flow improved from negative $4.0 million in 2026-Q1 to positive $121.1 million in 2026-Q2. Management projects full-year 2026 cash flow from operations between $300 million and $325 million. Net working capital was 19.0% of annualized net revenue in 2026-Q1. The trajectory shows improving cash flow and working capital management.
“Cash flow from operations for fiscal 2026 is now expected to be in the range of $300 million to $325 million.”
“Operating cash flow in fiscal year 2026 is expected to be between $275 million and $300 million.”
Breaks if: YoY revenue growth falls below 5% in FY26
Grow net revenue by mid-single digits in 2026 via pricing initiatives, acquisitions, and organic growth in key segments.
Stated in 2 of last 2 quarters. Revenue increased from $770.8 million in 2026-Q1 to $950.3 million in 2026-Q2, reflecting growth momentum. Management updated 2026 guidance to mid-single digit revenue growth, supported by pricing and acquisitions, indicating delivery on this priority.
“Net revenue for fiscal 2026 is still expected to be up mid-single digits.”
“Net revenue for fiscal 2026 is now expected to be up mid-single digits.”
Breaks if: Acquisition fails to close by 2026 year-end or synergy targets delayed beyond 2031
Complete acquisition of AMS to extend capabilities in high-growth medical adhesives, increase TAM by $15B, and accelerate path to >20% EBITDA margin with $55M synergies.
Newly stated in 2026-Q2. Management announced the acquisition of Advanced Medical Solutions to expand the medical segment, increasing TAM by $15 billion and targeting $55 million in run-rate synergies by 2031. This strategic move aligns with the goal of achieving >20% EBITDA margin. The transaction is expected to close by year-end, so delivery is pending.
“H.B. Fuller announces offer to acquire Advanced Medical Solutions to accelerate portfolio mix shift and >20% EBITDA margin target.”
Overall, FUL's multi-year view is cautiously optimistic, contingent on execution and market conditions. Not investment advice.